Search - tctmd.com

Displaying 1 - 20 of 115

Sort: Relevancy | Date

News Conference News AHA 2016

Proton Pump Inhibitor Use Tied to Elevated Ischemic Stroke Risk

Todd Neale

November 16, 2016

News Conference News AHA 2016

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

Todd Neale

November 14, 2016

News Conference News AHA 2016

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

Yael L. Maxwell

November 13, 2016

News Daily News

高强度他汀类药物治疗在 CVD 患者中实现超过中等强度他汀类药物的生存获益

Michael O'Riordan

November 10, 2016

News Daily News

High-Intensity Statin Therapy Offers Survival Benefit Over Moderate-Intensity Statins in CVD Patients

Michael O'Riordan

November 10, 2016

News Daily News

El Tratamiento con Estatinas de Alta Intensidad Ofrece una Mayor Supervivencia sobre las Estatinas de Intensidad Moderada en Pacientes con Enfermedad Cardiovascular

Michael O'Riordan

November 10, 2016

News Daily News

Newest Atherosclerosis Risk Calculator Aims to Adjust Predictions as Prevention Tactics Kick In

Yael L. Maxwell

November 10, 2016

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2016

Caitlin E. Cox

October 29, 2016

News Daily News

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

Michael O'Riordan

October 18, 2016

News Daily News

AHA 提供他汀类药物和心血管药物药物相互作用指导

Michael O'Riordan

October 18, 2016

News Daily News

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

Michael O'Riordan

October 18, 2016

News Daily News

EUCLID:替卡格雷相比氯吡格雷对有症状 PAD 患者预防心血管事件没有更大的好处

Shelley Wood

October 07, 2016

News Daily News

EUCLID: Ticagrelor Holds No Edge Over Clopidogrel for Preventing Atherothrombotic Events in Symptomatic PAD Patients

Shelley Wood

October 07, 2016

News Daily News

Ensayo EUCLID: Ticagrelor No es Más Beneficioso que Clopidogrel en la Prevención de Episodios CV en Pacientes con EAP Sintomática

Shelley Wood

October 07, 2016

News Daily News

CAC Screening Stratifies CVD Event Risk in Statin-Eligible Patients: Heinz Nixdorf Recall Study

Michael O'Riordan

September 22, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

September 20, 2016

News Daily News

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Michael O'Riordan

September 16, 2016

News Daily News

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Michael O'Riordan

September 16, 2016

News Daily News

Demasiados Elementos en Juego: La Existencia de Diferentes y Discordantes Directrices Hace que la Valoración del Riesgo de ECV sea Confusa

Michael O'Riordan

September 16, 2016

News Daily News

短期 DAPT 不适合所有人，尤其是复杂 PCI 之后

Yael L. Maxwell

September 02, 2016

Advertisement

Proton Pump Inhibitor Use Tied to Elevated Ischemic Stroke Risk

Rivaroxaban-Based Double or Triple Therapy Cuts Bleeding in Patients With A-fib Undergoing PCI: PIONEER AF-PCI

Ticagrelor Fails to Best Clopidogrel in Preventing CV Events in PAD Patients

高强度他汀类药物治疗在 CVD 患者中实现超过中等强度他汀类药物的生存获益

High-Intensity Statin Therapy Offers Survival Benefit Over Moderate-Intensity Statins in CVD Patients

El Tratamiento con Estatinas de Alta Intensidad Ofrece una Mayor Supervivencia sobre las Estatinas de Intensidad Moderada en Pacientes con Enfermedad Cardiovascular

Newest Atherosclerosis Risk Calculator Aims to Adjust Predictions as Prevention Tactics Kick In

TCTMD’s Top 10 Most Popular Stories for October 2016

La AHA Facilita las Interacciones Farmacológicas entre Estatinas y Fármacos contra la Enfermedad Cardiovascular

AHA 提供他汀类药物和心血管药物药物相互作用指导

AHA Provides Guidance on Drug-Drug Interactions With Statins and CVD Medications

EUCLID:替卡格雷相比氯吡格雷对有症状 PAD 患者预防心血管事件没有更大的好处

EUCLID: Ticagrelor Holds No Edge Over Clopidogrel for Preventing Atherothrombotic Events in Symptomatic PAD Patients

Ensayo EUCLID: Ticagrelor No es Más Beneficioso que Clopidogrel en la Prevención de Episodios CV en Pacientes con EAP Sintomática

CAC Screening Stratifies CVD Event Risk in Statin-Eligible Patients: Heinz Nixdorf Recall Study

Amgen Announces Positive Top-Line Results From Phase 3 GLAGOV Imaging Study Of Repatha® (Evolocumab)

太多主角：不同指南 CVD 风险评估存在混淆和不一致

Many Guidelines, Mixed Consensus: Different CVD Risk Guidelines Cause Confusion in Practice

Demasiados Elementos en Juego: La Existencia de Diferentes y Discordantes Directrices Hace que la Valoración del Riesgo de ECV sea Confusa

短期 DAPT 不适合所有人，尤其是复杂 PCI 之后

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content